Company Description
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers.
The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H.
Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH.
The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017.
Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 557 |
| CEO | Dr. Frederick G. Vogt Esq., J.D., Ph.D. |
Contact Details
Address: 825 Industrial Road, 4th Floor San Carlos, California 94070 United States | |
| Phone | (650) 260-7120 |
| Website | iovance.com |
Stock Details
| Ticker Symbol | IOVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001425205 |
| CUSIP Number | 462260100 |
| ISIN Number | US4622601007 |
| Employer ID | 75-3254381 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Frederick G. Vogt Esq., J.D., Ph.D. | Interim Chief Executive Officer, President, General Counsel and Corporate Secretary |
| Jean-Marc Bellemin M.B.A. | Chief Financial Officer, Principal Accounting Officer and Treasurer |
| Dr. Igor P. Bilinsky | Chief Operating Officer |
| Dr. Friedrich Graf Finckenstein M.D. | Chief Medical Officer |
| Sara Pellegrino | Vice President of Investor Relations and Public Relations |
| Tracy Winton | Senior Vice President of Human Resources |
| Howard B. Johnson M.B.A. | Chief Business Officer |
| James Ziegler M.B.A. | Executive Vice President of Commercial |
| Dr. Raj K. Puri M.D., Ph.D. | Executive Vice President of Regulatory Strategy and Translational Medicine |
| Brian Shew M.B.A. | Senior Vice President and Head of Digital and Information Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | 8-K | Current Report |
| Jun 11, 2024 | 8-K | Current Report |
| Jun 3, 2024 | 8-K | Current Report |
| May 24, 2024 | 8-K | Current Report |
| May 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 10, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 1, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |